Demo
ALNY Nasdaq· Alnylam Pharmaceuticals Inc
FundamentalsNews digest Peer analysis
Login
ALNY Nasdaq· Alnylam Pharmaceuticals Inc
Earnings report Q4 2023

ALNYLAM PHARMACEUTICALS, INC. Reports Strong Revenue Growth in Latest Quarter

Segments of Revenue

ALNYLAM PHARMACEUTICALS, INC. experienced significant growth in its revenue during the latest quarter. The company's revenue can be divided into three main segments: net product revenues, net revenues from collaborations, and royalty revenue.

  • Net product revenues increased from $894.33 million in the previous year to $1.24 billion in the latest quarter, reflecting a substantial growth of 38%. This increase can be attributed to the successful sales performance of the company's products.

  • Net revenues from collaborations also showed remarkable growth, reaching $546.19 million in the latest quarter compared to $134.91 million in the previous year. This significant increase of 305% can be attributed to successful collaborations with Roche, Regeneron Pharmaceuticals, Novartis AG, and other partners.

  • Royalty revenue increased from $8.18 million in the previous year to $40.63 million in the latest quarter, reflecting a growth of 397%. This growth can be attributed to the successful commercialization of licensed products.

Strengths

ALNYLAM PHARMACEUTICALS, INC. demonstrated several strengths based on its financial performance. The company achieved strong revenue growth across all segments, indicating the effectiveness of its product sales and collaborations. The increase in net product revenues can be attributed to the successful commercialization of its products, while the growth in net revenues from collaborations highlights the company's ability to form successful partnerships. Additionally, the significant increase in royalty revenue indicates the successful licensing of its products.

Challenges

Despite the strong revenue growth, ALNYLAM PHARMACEUTICALS, INC. faced challenges in managing its operating costs and expenses. The company experienced a loss from operations of $282.18 million in the latest quarter. This loss can be attributed to the high costs of goods sold, collaborations, research and development, and selling, general, and administrative expenses. The company needs to carefully manage its expenses to improve its profitability.

Noteworthy

It is noteworthy that ALNYLAM PHARMACEUTICALS, INC. experienced a substantial increase in its revenue from collaborations, particularly with Roche, Regeneron Pharmaceuticals, and Novartis AG. These collaborations have contributed significantly to the company's overall revenue growth.

Summary

ALNYLAM PHARMACEUTICALS, INC. reported strong revenue growth in the latest quarter, driven by increased net product revenues, net revenues from collaborations, and royalty revenue. The company demonstrated strengths in successfully commercializing its products, forming successful collaborations, and licensing its products. However, the company faced challenges in managing its operating costs and expenses, resulting in a loss from operations. ALNYLAM PHARMACEUTICALS, INC. should focus on optimizing its expenses to improve profitability. The significant increase in revenue from collaborations, particularly with Roche, Regeneron Pharmaceuticals, and Novartis AG, is noteworthy and highlights the company's ability to form successful partnerships.

Source documents

Form 10-K  filed on Feb 15, 2024
81 pages scanned

Reference data

Company financials Q4 revenue 440M
Analyst estimates Q4 EPS beat by 0.20%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.